Jenburkt Pharmaceuticals (524731) Q3 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 24/25 earnings summary
21 Nov, 2025Executive summary
Standalone unaudited financial results for the quarter and nine months ended 31st December 2024 were approved and reviewed by the Board and Audit Committee.
Limited review by auditors found no material misstatements or non-compliance with SEBI regulations.
Financial highlights
Revenue from operations for Q3 FY25 was ₹3,689.30 lakhs, up from ₹3,565.98 lakhs in Q3 FY24.
Profit before tax for Q3 FY25 stood at ₹951.33 lakhs, compared to ₹784.04 lakhs in Q3 FY24.
Net profit after tax for Q3 FY25 was ₹650.75 lakhs, up from ₹540.44 lakhs in Q3 FY24.
Total comprehensive income for Q3 FY25 reached ₹593.16 lakhs, compared to ₹646.75 lakhs in Q3 FY24.
Earnings per share (EPS) for Q3 FY25 was ₹14.75, up from ₹12.25 in Q3 FY24.
Outlook and guidance
The company continues to operate exclusively in the pharmaceuticals segment, with no segment-wise reporting applicable.
Latest events from Jenburkt Pharmaceuticals
- H1 revenue advanced, but PAT and EPS declined year over year.524731
Q2 26/27 - Q1 FY27 profit after tax declined to ₹588.56 lakhs, with EPS at ₹13.34.524731Q1 26/27
- Revenue and profit rose, dividend declared, and audit opinion unmodified for FY 2025-26.524731Q4 25/26
- Q3 FY26 saw higher revenue but lower profit after tax and EPS, with added labour cost provisions.524731Q3 25/26
- Revenue and net profit rose year-over-year, with EPS at ₹23.03 and strong cash flow.524731Q2 25/26
- Revenue and profit after tax rose year-over-year, with EPS reaching ₹17.66.524731Q1 25/26
- Strong revenue and profit growth reported for Q2 FY25, with higher EPS and cash flow.524731Q2 24/25
- Q1 FY25 saw higher revenue, profit, and EPS, with continued focus on pharmaceuticals.524731Q1 24/25
- FY25 net profit rose 23% to ₹3,206 lakh; ₹18/share dividend declared.524731Q4 24/25